Nephrotic Syndrome Clinical Trials
Here is the most popular medical study for nephrotic syndrome
Popular filter options for nephrotic syndrome trials
Nephrotic Syndrome Clinical Trials With No Placebo
View 10 nephrotic syndrome medical studies that do not have a placebo group.
Angiotensin Receptor Blocker and Endothelin Receptor Antagonist
Sparsentan for Proteinuric Kidney Disease
This trial is testing a drug to see if it is safe, works well, and is tolerated by patients. It will also assess how much protein is in urine after taking the drug.
Monoclonal Antibodies
Rituximab + Cyclosporine for Glomerulonephritis
This trial is testing the safety and effectiveness of combining two drugs to treat membranous nephropathy, a kidney disease associated with damage to the walls of the glomeruli. The first drug, rituximab, is an immunosuppressant that attempts to reduce the activity of the immune system. The second drug, cyclosporine, is a blood pressure lowering medication. The trial will last up to 2 years, and participants will have frequent blood and urine tests.
Frequently Asked Questions
Introduction to nephrotic syndrome
What are the top hospitals conducting nephrotic syndrome research?
Nephrotic syndrome, a complex kidney disorder that primarily affects children, has garnered the attention of several prestigious hospitals conducting clinical trials. Cohen Children's Medical Center in New Hyde Park, for instance, is actively engaged in two nephrotic syndrome trials and has thus far contributed two studies to the field since recording their first trial in 2022. In Philadelphia, the renowned Children's Hospital leads with two ongoing trials and a total of four completed studies on nephrotic syndrome since initiating research efforts back in 2001. The National Institutes of Health Clinical Center located in Bethesda is also at the forefront of this field with its commitment to exploring new treatment options through two active clinical trials and three historically significant investigations dating all the way back to1992.
Meanwhile, across the country in Los Angeles at Cedars-Sinai Medical Center, researchers are equally dedicated to advancing our understanding of nephrotic syndrome. With two currently running clinical trials and an impressive seven prior studies conducted since their first investigation began in 2011.Cedars Sinai continues leading efforts towards tackling this challenging condition head-on.In Shreveport's Northwest Louisiana Nephrology Institute,the focus remains steadfast on finding effective solutions for patients suffering from nephrotic syndrome.Two current active clinical tests complement their previous groundbreaking contributions comprisingtwo noteworthy experiments which were initiated as recently as2018.These institutions' dedication reflects not only a determination shared by medical professionals but also a crucial step forward toward improved outcomes and enhanced quality of life for those affected by this debilitating renal ailment.With continued collaboration among these top hospitals nationwide,nephrotic syndromepatients can hope for brighter prospects ahead
Which are the best cities for nephrotic syndrome clinical trials?
When it comes to clinical trials for nephrotic syndrome, several cities emerge as top contenders. Minneapolis, Minnesota and Bethesda, Maryland each have 4 active trials exploring treatments like Sparsentan, Belimumab, Rituximab Infusion, and more. New Hyde Park, New york and Philadelphia, Pennsylvania follow closely behind with 3 ongoing studies focused on interventions such as Sparsentan and Belimumab. Lastly, Los Angeles, California also has 3 active trials investigating VB119, Handgrip interventions, abnormal CRT measures among others. These cities provide individuals living with nephrotic syndrome access to cutting-edge clinical research that could potentially improve their condition and overall quality of life.
Which are the top treatments for nephrotic syndrome being explored in clinical trials?
Exciting developments are underway in the field of nephrotic syndrome treatment, with several promising options being explored in clinical trials. Vericiguat, a newcomer to the scene since 2023, is currently undergoing one active trial dedicated to this condition. Similarly, VB119 and sparsentan show great potential as they too each have one ongoing trial and were introduced in 2022 and 2021 respectively. Another innovative approach being investigated is the diuretic tuner, also with one active trial scheduled for completion in 2023. These advancements hold promise for improving outcomes for individuals living with nephrotic syndrome.
What are the most recent clinical trials for nephrotic syndrome?
Exciting advancements are being made in the field of nephrotic syndrome, with recent clinical trials shedding light on potential treatments. One such trial focuses on vericiguat, a medication currently in Phase 2 testing for its efficacy in managing nephrotic syndrome. Another study explores the use of obinutuzumab (Group A) as a potential treatment option for this condition, with Phase 3 results expected to provide valuable insights. ADX-629 is also undergoing Phase 2 trials to assess its effectiveness against nephrotic syndrome symptoms. These studies contribute to our growing understanding and may offer new hope for patients battling this debilitating condition.
What nephrotic syndrome clinical trials were recently completed?
A recent clinical trial investigating potential treatments for nephrotic syndrome has concluded, marking a significant milestone in the field. The study focused on Apixaban 5 MG and was sponsored by the University of North carolina, Chapel Hill. Completed in April 2021, this trial sheds light on the potential effectiveness of Apixaban as a therapeutic option for patients with nephrotic syndrome. These findings provide hope and valuable insights into managing this complex condition, ultimately aiming to improve patient outcomes and quality of life.